SYKBy Calypso Research6 min read

Stryker Corporation (SYK) Q4 2025 Earnings Analysis

Stryker Strikes Gold with $7.2B Revenue Surge

Key Takeaways

Stryker Corporation (SYK) reported Q4 2025 earnings with revenue of $7.2B, representing a +11.4% year-over-year change. The stock moved +4.3% on earnings day.

The bull case: Strong Mako performance, robust procedural demand, and international product launches drive consistent high-growth potential.

The bear case: Incremental tariff impacts and regulatory delays in international markets may constrain margin and growth expansion.

Financial Highlights

  • Revenue: $7.2B (+11.4% YoY)
  • Gross Profit: $4.7B (65.2% margin, +3.2% YoY)
  • Operating Income: $2.0B (27.3% margin, +1.5% YoY)
  • Net Income: $849M
  • TTM Revenue: $25.1B

Stock Performance

  • Earnings Day Move: +4.3%
  • Year-to-Date: +10.5%
  • 1-Year Return: -0.8%
  • vs. S&P 500 (since earnings): -2.3%
  • vs. Nasdaq (since earnings): -0.6%

View live SYK data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Stryker Corporation's Q4 2025 earnings call:

Confidence in 2026 Growth Guidance and Potential for Fifth Year of Double-Digit Organic Growth

Sentiment: Positive

"Given the order book, given the strength of the Mako performance we had in the fourth quarter... we really feel more positive, I'd say modestly more positive this year than we did one year ago." — Kevin Lobo
"10% is certainly possible. But it does depend on a lot of things that are in the macro environment procedure growth. But we do have a strong order book." — Kevin Lobo

Margin Expansion Amid Tariff Headwinds

Sentiment: Positive

"We expect full-year tariff impacts to be approximately $400 million, which includes an incremental $200 million compared to 2025... and you'll see we're going to drive meaningful op margin expansion in the face of this extra $200 million." — Preston Wells
"If we had had this level of tariffs seven, eight years ago, you would not be seeing us continue to drive expansion to the level that we are. So, we have built some earnings power in our company." — Kevin Lobo

Mako Surgical System's Performance and New Applications

Sentiment: Positive

"Mako-four has been an absolute home run... this is the first time we've had a change of the actual robot to a new robot since we bought Mako." — Kevin Lobo
"Shoulder is going to be really exciting when we bring that to the market... the harder the procedure is, the more Mako brings value. So we are in the pole position, and we're going to continue to press our lead." — Kevin Lobo

Pricing Dynamics Across MedSurg and Orthopedics

Sentiment: Positive

"The fundamentals still remain the same, and we would expect to continue to see a pretty steady cadence of price coming through from [MedSurg] in 2026." — Preston Wells
"MedSurg will be positive. The orthopedics will be slightly negative. And the two will net to something similar to what we experienced this year going forward." — Kevin Lobo

Opportunities in International Markets and Regulatory Challenges

Sentiment: Mixed

"The opportunity in international is significant. And as these products do reach these markets, you should expect to see a pretty similar dynamic as to what you see in the United States." — Kevin Lobo
"Europe has woken up to the reality that they are stunting innovation and not giving patients access to products in a timely manner... this will help us accelerate the launch of our products." — Kevin Lobo

Bull Case

Strong Mako performance, robust procedural demand, and international product launches drive consistent high-growth potential.

Bear Case

Incremental tariff impacts and regulatory delays in international markets may constrain margin and growth expansion.

Looking Ahead

With revenue growing +11.4% year-over-year, the key question is whether Stryker Corporation can sustain this growth trajectory, particularly around confidence in 2026 Growth Guidance and Potential for Fifth Year of Double-Digit Organic Growth. With operating margins at 27.3%, margin trends will remain a focal point. The market's positive reaction on earnings day suggests confidence in management's direction, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Stryker Corporation's revenue in Q4 2025?

Stryker Corporation reported Q4 2025 revenue of $7.2B, representing a +11.4% year-over-year change.

Did Stryker Corporation beat earnings expectations in Q4 2025?

The stock rose +4.3% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: Strong Mako performance, robust procedural demand, and international product launches drive consistent high-growth potential.

What is the bull case for SYK stock?

The bull case for SYK centers on: Strong Mako performance, robust procedural demand, and international product launches drive consistent high-growth potential.

What is the bear case for SYK stock?

The bear case for SYK centers on: Incremental tariff impacts and regulatory delays in international markets may constrain margin and growth expansion.

How has SYK stock performed since its Q4 2025 earnings?

SYK moved +4.3% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +2.3% since earnings. Year-to-date, the stock has returned +10.5%.

Browse all 400+ earnings reports →

Learn More

Analyze SYK in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Stryker Corporation and 400+ other stocks, explore the full platform.

Open SYK on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.